BrainsWay (BWAY) Q2 2026 earnings review
Record Placements and Expanding Margins Drive Raised Guidance
BrainsWay delivered another exceptionally strong quarter, with Q2 2026 revenue increasing 35% YoY to $17.1 million. The company's strategic pivot to an enterprise lease model continues to yield compounding benefits: Remaining Performance Obligations (RPOs) surged to $80.4 million, providing immense revenue visibility. Crucially, the top-line growth is rapidly translating to the bottom line. Adjusted EBITDA more than doubled YoY to $3.5 million, driving margins to a record 20%. Armed with strong system placements (125 in the quarter) and widening payer coverage for its SWIFT protocol, management confidently raised full-year FY26 guidance across all key profitability metrics.
🐂 Bull Case
The company's cost structure is heavily fixed. As lease revenues pile up from the expanding 1,949-unit installed base, incremental gross profit is flowing directly to the bottom line, driving the Adjusted EBITDA margin from 11% a year ago to 20% today.
The FDA-cleared SWIFT protocol reduces the acute treatment phase from 20-30 days to just 6 days. This drastic improvement in patient convenience and clinic throughput is accelerating new system orders and payer coverage adoption.
🐻 Bear Case
Despite Net Income rising, Operating Cash Flow in Q2 2026 was $6.3M, down 51% YoY from $12.8M in Q2 2025. This was driven by a much smaller build in deferred revenues, signaling that upfront cash collections from new leases may be normalizing.
BrainsWay is deploying capital into minority stakes (Hopemark, Radial Health, Neurolief). While these secure dedicated sales channels, the actual financial ROI depends entirely on the operational success of these third-party entities.
⚖️ Verdict: 🟢
Bullish. BrainsWay is demonstrating textbook SaaS-like operating leverage within a med-tech hardware framework. The compounding nature of its RPO backlog heavily de-risks future revenue growth.
Key Themes
Enterprise Lease Model Accumulates Predictable Revenue
The transition to multi-year enterprise lease agreements is the cornerstone of BrainsWay's current financial success. By prioritizing long-term recurring revenue over one-off capital equipment sales, the company has built a Remaining Performance Obligation (RPO) backlog of $80.4 million, up 30% YoY. This insulates the company against quarter-to-quarter capital spending volatility at clinics and guarantees a high-margin revenue floor for upcoming periods.
SWIFT Protocol Revolutionizing Clinic Economics
The SWIFT (Short-course with Intrinsic Field Targeting) accelerated Deep TMS protocol is emerging as the primary driver of new demand. By condensing the acute treatment phase to several days, it radically improves patient adherence and allows clinics to process significantly more patients per machine. The presentation of 12-month durability data and a 83.5% response rate in PTSD/MDD comorbid patients at the CTMSS meeting provides the clinical bedrock needed to expand insurer coverage, which the company noted is accelerating.
Regulatory Enhancements Uncapping Addressable Market
BrainsWay's growth is being heavily supported by evolving reimbursement landscapes. Beyond just securing coverage for adolescent depression, payers like Optum, the VA, and TRICARE are now permitting trained nurse practitioners to administer Deep TMS. By removing the bottleneck of requiring a psychiatrist to actively administer the treatment, clinics can scale their TMS operations much faster.
Minority Investment Strategy Broadening the Ecosystem
Management continues to aggressively execute its strategy of taking minority stakes in mental health providers. Following earlier investments, BrainsWay added Hopemark Health and Radial Health to its portfolio in Q2 2026. This ecosystem-building approach guarantees a captive audience for Deep TMS systems, effectively buying distribution channels. However, it requires upfront capital and blurs the lines between being a pure-play technology provider and a clinic operator.
Operating Cash Flow Diverges from Profitability
A specific contradiction to the pristine income statement is found in the cash flow statement. Operating Cash Flow (OCF) in Q2 2026 was $6.3M, a steep deceleration from the $12.8M generated in Q2 2025, despite Net Income rising 34%. This $6.5M negative swing was entirely driven by changes in working capital—specifically, deferred revenues only increased by $2.3M this quarter compared to an $8.4M jump in the prior-year period. This indicates that while the lease book is growing, the influx of upfront cash payments is normalizing.
Pipeline Dependency and FDA Timelines
Future growth requires the successful clearance of new indications (such as PTSD comorbidity) and partner devices like Neurolief's ProlivRx. With management previously noting slow administrative timelines at the FDA, any delays in regulatory clearance for these expansion catalysts could cause the high-30% growth rates to plateau.
Geopolitical Exposure Risk
With substantial operations and headquarters in Jerusalem, Israel, the company remains exposed to broader macroeconomic and geopolitical volatility in the Middle East. While management has previously confirmed no operational disruptions, any escalation could risk supply chain or manufacturing stability for the Deep TMS systems.
Other KPIs
Accelerating. The installed base continues to march toward the 2,000 milestone, fueled by a record 125 shipments in Q2 2026 (a 42% YoY increase). This expanding footprint is the direct engine for the company's RPO and recurring revenue growth.
Stable. Gross profit reached $12.8M on $17.1M of revenue. BrainsWay is maintaining excellent mid-70s gross margins despite inflationary pressures, validating the high value-add nature of its proprietary H1 coil technology and lease contracts.
Guidance
Accelerating. Raised from the previous $66-$68M range. The new midpoint ($69.0M) implies aggressive 30% to 34% YoY growth compared to FY25. This suggests high confidence in both new system placements and SWIFT-driven utilization in the back half of the year.
Accelerating. Raised from the previous $12-$14M range. The updated guidance implies a massive 90% to 100% growth over FY25, highlighting the extreme operating leverage inherent in the enterprise lease model as R&D and SG&A expenses scale slower than gross profit.
Accelerating. Raised from 13%-14%. Reflects tight cost discipline. Given Q2 2026 already hit 14%, management expects to sustain this peak efficiency level through the remainder of the year.
Key Questions
Deferred Revenue Dynamics
Operating cash flow saw a sharp YoY decline due to a smaller build in deferred revenues compared to Q2 2025. Does this reflect a shift in contract structures requiring less upfront cash from enterprise clients, or simply timing of collections?
Minority Investment ROI
With Hopemark Health and Radial Health added to the portfolio, how exactly is BrainsWay tracking and measuring the financial return on these investments? Are they mandated to exclusively lease Deep TMS systems?
PTSD FDA Timeline Update
Given previous comments regarding slow FDA administrative processes, what is the latest, most realistic timeline for securing clearance for the PTSD comorbidity indication, and when will that begin contributing to revenue?